LivaNova (NASDAQ:LIVN – Get Rating) released its quarterly earnings results on Wednesday. The company reported $0.48 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.48, MarketWatch Earnings reports. The company had revenue of $240.20 million during the quarter, compared to analysts’ expectations of $231.57 million. LivaNova had a positive return on equity of 9.31% and a negative net margin of 12.78%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.35 earnings per share. LivaNova updated its FY22 guidance to $2.50-$2.80 EPS.
Shares of NASDAQ LIVN opened at $74.57 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.97 and a quick ratio of 0.82. The firm has a fifty day moving average of $79.51 and a 200-day moving average of $80.74. LivaNova has a 52-week low of $68.68 and a 52-week high of $93.89.
In other LivaNova news, CEO Damien Mcdonald sold 2,784 shares of LivaNova stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $81.50, for a total transaction of $226,896.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $80.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. Insiders sold a total of 5,784 shares of company stock worth $470,316 over the last ninety days. Corporate insiders own 0.37% of the company’s stock.
Several research analysts recently weighed in on the stock. UBS Group raised shares of LivaNova from a “neutral” rating to a “buy” rating and set a $96.00 target price for the company in a research note on Thursday, February 24th. Needham & Company LLC reduced their price objective on shares of LivaNova from $120.00 to $106.00 and set a “buy” rating on the stock in a research note on Thursday, February 24th. Wolfe Research assumed coverage on shares of LivaNova in a research report on Tuesday, April 5th. They set an “outperform” rating and a $95.00 target price on the stock. Zacks Investment Research downgraded LivaNova from a “hold” rating to a “sell” rating in a report on Saturday, February 26th. Finally, StockNews.com initiated coverage on LivaNova in a report on Thursday, March 31st. They set a “hold” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $101.57.
About LivaNova (Get Rating)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.